Inclusion Criteria:

          -  Histologically or cytologically documented NSCLC; Patients must be M0. Patients with
             T1-T2 with N2 or T3N1-2 are eligible, if inoperable. Patients with T4 with any N or
             any T with N2 or N3 disease are eligible if unresectable.

          -  Patients with tumors adjacent to a vertebral body are eligible as long as all gross
             disease can be encompassed in the radiation boost field. The boost volume must be
             limited to < 50% of the ipsilateral lung volume.

          -  Patients with Zubrod performance status 0-1

          -  Adequate hematologic function

          -  FEV1 with ≥ 1200 cc or ≥ 50% predicted

        Exclusion Criteria:

          -  Prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for
             any reason and/or surgical resection of present cancer

          -  Exudative, bloody, or cytologically malignant effusions

          -  Prior therapy with any molecular targeted drugs (for lung cancer)

          -  Active pulmonary infection not responsive to conventional antibiotics

          -  Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena
             cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease
             >2 (see Appendix B) within 3 months before entry; or presence of cardiac disease that,
             in the opinion of the Investigator, increases the risk of ventricular arrhythmia.

          -  Patients with > grade 1 neuropathy